EU Suspends Avandia; Pressure On Open Decision-Making May Stay
This article was originally published in The Pink Sheet Daily
Executive Summary
Product will be taken off the market "within the next few months," EMA says as it holds an unprecedented press conference.
You may also be interested in...
EU's CHMP Delays Decision On Actos, Restricts Use Of An NSAID And Cytoprotective
Europe's top regulatory advisory panel wants further analysis of Actos' link with bladder cancer, but recommends limiting indications for the NSAID nimesulide and adding contraindications for the cytoprotective dexrazoxane.
EU's CHMP Delays Decision On Actos, Restricts Use Of An NSAID And Cytoprotective
Europe's top regulatory advisory panel wants further analysis of Actos' link with bladder cancer, but recommends limiting indications for the NSAID nimesulide and adding contraindications for the cytoprotective dexrazoxane.
Another Setback For Glitazones: Germany Withdraws Reimbursement For The Diabetes Drugs
Federal joint committee decision means GSK's Avandia and Takeda's Actos no longer will be reimbursed in Germany other than in exceptional cases.